PLUS1
Best deals to access real time data! |
|
Canadian Level 1 + USA
Monthly Subscription
for only
|
|
CHART Trader
Monthly Subscription
for only
|
|
Big Cap Pro
Monthly Subscription
for only
|
|
VAT not included
|
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Galmed Pharmaceuticals Ltd | GLMD | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | High Price | Low Price | Open Price | Close Price | Last Traded  |
|
|---|---|---|---|---|---|---|---|---|
| -0.32 | -5.25% | 5.77 | 6.25 | 5.6889 | 6.07 | 6.09 | 18:03:53 |
| Bid Price | Ask Price | Spread | Spread % | News | |
|---|---|---|---|---|---|
| 5.61 | 6.85 | 1.24 | 18.1% | - | - |
| Stock Trades | Traded Volume | VWAP | Dollar Volume | Average Volume | 52 Week Range |
|---|---|---|---|---|---|
| 644 | 93,465 | $ 5.86 | $ 547,276 | 145,717 | 3.4179 - 9.37 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 15:59:38 | 450 | $ 5.77 | USD |
Galmed Pharmaceuticals Financials
| Market Cap | Shares in Issue | Profit/Loss | Earnings Per Share (EPS) | PE Ratio | Float |
|---|---|---|---|---|---|
| $ 121.89M | 21.12M | $ -9.86M | -0.57 | - | 21.12M |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ - | 0.00% | - | - |
Galmed Pharmaceuticals News
| Date | Time | Source | News Article |
|---|---|---|---|
| 11/06/2019 | 07:11 | Edgar (US Regulatory) | Report of Foreign Issuer (6-k) |
| 11/06/2019 | 07:00 | PR Newswire (US) | Galmed Pharmaceuticals Provides Business Update and Reports.. |
| 10/31/2019 | 09:04 | Edgar (US Regulatory) | Report of Foreign Issuer (6-k) |
| 10/31/2019 | 08:30 | PR Newswire (US) | Galmed Pharmaceuticals to Present New Data on Aramchol.. |
| 10/30/2019 | 08:30 | PR Newswire (US) | Galmed Pharmaceuticals to Report Third Quarter 2019.. |
| 9/26/2019 | 08:12 | Edgar (US Regulatory) | Report of Foreign Issuer (6-k) |
| 9/26/2019 | 08:00 | PR Newswire (US) | Galmed Pharmaceuticals Initiated ARMOR, a Phase 3/4.. |
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical GLMD Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 6.52 | 6.683 | 5.6889 | 6.28 | 59,494 | -0.75 | -11.5% |
| 1 Month | 5.82 | 7.2375 | 5.55 | 6.37 | 94,594 | -0.05 | -0.86% |
| 3 Months | 4.24 | 7.38 | 4.10 | 5.97 | 120,307 | 1.53 | 36.08% |
| 6 Months | 5.85 | 7.38 | 3.4179 | 5.35 | 99,411 | -0.08 | -1.37% |
| 1 Year | 7.77 | 9.37 | 3.4179 | 6.45 | 95,859 | -2.00 | -25.74% |
| 3 Years | 4.08 | 27.06 | 3.4179 | 11.44 | 141,531 | 1.69 | 41.42% |
| 5 Years | 6.34 | 27.06 | 2.78 | 10.61 | 102,675 | -0.57 | -8.99% |
Galmed Pharmaceuticals Description
| Galmed Pharmaceuticals Ltd is a biopharmaceutical company. It focuses on the development and commercialization of once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones utilizing its synthetic fatty-acid/bile-acid conjugate (FABAC), called aramchol. Its product, aramchol, is a disease-modifying treatment for fatty liver disorders, including Non-Alcoholic Steato-hepatitis. Aramchol affects liver fat metabolism and has been shown in a Phase IIa clinical study to reduce liver fat content, as well as improve metabolic parameters associated with Nonalcoholic steatohepatitis. |
